Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001983007 | SCV002239703 | pathogenic | Combined oxidative phosphorylation defect type 14 | 2023-05-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the FARS2 protein in which other variant(s) (p.Gly309Ser) have been determined to be pathogenic (PMID: 28043061, 28419689, 30177229). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with FARS2-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 4-6 of the FARS2 gene. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to disrupt the C-terminus of the protein. |